What Is VHT? Vanguard Health Care ETF

VHT is the Vanguard Health Care ETF, launched in January 2004 as part of Vanguard's low-cost sector lineup. It tracks the MSCI US Investable Market Health Care 25/50 Index, a market-cap-weighted benchmark of US health-care stocks with caps that keep any single name and the largest holdings from dominating too heavily, and it charges a 0.09% expense ratio.

The fund holds more than 400 companies spanning large pharmaceuticals, biotech, health insurers, medical devices, and life-science tools. With roughly $18 billion in assets, VHT is one of the larger health-care ETFs, offering broad, cheap exposure to the entire US health-care sector in a single ticker.

Approximate weights as of mid-2026; refresh quarterly from Vanguard's fund page. Each ticker links to its individual stock guide in Walnut.

VHT is broad but top-anchored. Eli Lilly is around 12% of the fund and Johnson & Johnson about 9%, followed by AbbVie, Merck, and UnitedHealth Group. The next tier includes Amgen, Thermo Fisher Scientific, Abbott Laboratories, Gilead Sciences, and Intuitive Surgical. The top 10 make up roughly half of assets, while hundreds of smaller biotech, device, and services names fill the long tail.

By subsector VHT covers the full landscape: big pharma and biotech dominate, but the fund also holds managed-care insurers like UnitedHealth, device makers like Abbott and Intuitive Surgical, and life-science tools companies like Thermo Fisher. That mix means VHT captures both the stable, dividend-paying drugmakers and the higher-growth innovators in one basket.

VHT and State Street's XLV are the two leading health-care ETFs, and both are led by Eli Lilly and Johnson & Johnson. The difference is breadth versus liquidity. VHT tracks a broad MSCI index of more than 400 stocks, reaching deep into mid and small caps, while XLV holds only the ~60 health-care names in the S&P 500. Both charge 0.09%.

XLV is the more liquid fund, with higher trading volume and a deeper options market, favored by active traders. VHT offers far wider diversification into smaller biotech and device companies, appealing to buy-and-hold investors who want fuller sector coverage. Because both are cap-weighted and dominated by the same mega-cap drugmakers, their headline performance tends to be similar, though VHT's small-cap tail can create modest divergence.

Health care blends defensive stability with genuine growth, and VHT reflects both. Demand for drugs, care, and devices is relatively insensitive to the economy, giving the fund lower volatility than the broad market, while innovation in areas like GLP-1 obesity drugs, oncology, and medical robotics provides upside. Eli Lilly's rise on the GLP-1 boom has been a major recent driver of VHT's returns given its large weight.

The outlook rests on continued innovation against ongoing risks: drug-pricing legislation, patent cliffs as blockbuster drugs lose exclusivity, and political and regulatory pressure on insurers and drugmakers. Demographic tailwinds from aging populations support long-term demand, but the sector's concentration in a few mega-caps means a stumble at Lilly, J&J, or a major insurer can weigh heavily on the fund.

VHT suits investors who want low-cost, broadly diversified exposure to US health care as a core-satellite holding, combining defensive characteristics with long-term growth. Its breadth across pharma, biotech, insurers, and devices, plus a modest ~1.5% yield, makes it a one-ticker way to own the sector. The trade-offs: it is concentrated at the top, tilted toward a few large drugmakers, and exposed to pricing and regulatory risk.

How much, if any, belongs in your portfolio depends on your goals, time horizon, risk tolerance, and what you already own. Walnut is not an investment adviser and this is not a recommendation to buy or sell VHT; it is descriptive information to help you decide how the fund fits your own targets.

VHT trades on the NYSE Arca exchange and is available through any US brokerage, including Robinhood, Fidelity, Schwab, and Public. Many of these offer fractional shares, so you can buy a specific dollar amount instead of a whole share. VHT is liquid enough that spreads are tight and orders fill easily during market hours.

If you use Walnut, you can connect your brokerage to track VHT alongside the rest of your holdings, see how it maps to your target weights, and monitor how the health-care position performs over time. Walnut is the intelligence and tracking layer; the trade itself executes at your connected broker, and Walnut never places orders on its own.

ETFs are passive bundles; thematic baskets in Walnut let you concentrate within them. If you hold VHT as a core position, these are the themes you might layer on as satellites.

The bottom line on VHT: it is the broadest, low-cost way to own US health care, from Eli Lilly and J&J down to hundreds of smaller biotech and device names. It plays a core-satellite role, a diversified sector holding with a modest ~1.5% yield and a strong long-term growth profile, not an income vehicle.

Whether VHT is worth buying today depends more on your time horizon and what you already hold than on any single call. We walk through valuation, concentration, and what would have to be true for it to outperform from here in is VHT a buy?

VHT yields ~1.5% as of mid-2026, paid by passing through the dividends of its underlying holdings. For the payout schedule, history, and how the distributions are taxed, see VHT dividend: yield and schedule.